Genprex to Present TUSC2 Gene Research at GSA 2026 Meeting

Austin, Texas, United States, October 28, 2026

Genprex and Meharry Collaboration Investigates TUSC2 Biology

Genprex established its sponsored research collaboration with Meharry Medical College in 2024 to investigate the biological activities associated with REQORSA and the TUSC2 gene. The collaboration examines areas including mitochondrial metabolism, molecular aging, and their potential relationship to cancer. TUSC2 is a tumor-suppressor gene that plays a role in regulating cellular functions, and Genprex’s gene therapy approach is designed to restore tumor-suppressor activity by delivering this gene into cells. Through the collaboration, researchers are investigating how TUSC2 may be involved in cellular metabolism and stress-response pathways, alongside its established relevance to cancer biology. The research also explores molecular mechanisms associated with cellular aging and resilience. According to Genprex, the ongoing work with Meharry Medical College is expected to expand the investigation of TUSC2 in aging-related biological processes. These research efforts may provide additional insights into the gene’s broader biological functions and help identify areas for future scientific study.

TUSC2 Research Selected for GSA 2026 Poster Presentation

The research will be presented under the title “TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program.” The poster is scheduled for the Late Breaking Poster Session I on Wednesday, November 4, 2026, from 6:00 p.m. to 7:15 p.m. Eastern Time. The presentation will take place at the Gaylord National Resort & Convention Center, Exhibit Hall C-D, with abstract ID 2489375. Mark S. Berger, MD, Chief Medical Officer of Genprex, is identified as the presenter. The GSA Annual Scientific Meeting brings together researchers and professionals focused on aging and related scientific disciplines, providing a platform for sharing research findings and discussing developments in the field. Genprex expects the poster to become available on its website after the presentation, subject to applicable conference disclosure requirements. The scheduled presentation will give researchers an opportunity to review the work examining the relationship between TUSC2 gene therapy and cellular resilience in humans.

Potential Research Applications Beyond Oncology

The collaboration may help expand understanding of the biological activities of REQORSA® Gene Therapy, which is being developed primarily for cancer treatment. Genprex’s lead oncology candidate, quaratusugene ozeplasmid (Quar Oze), uses its non-viral ONCOPREX® Delivery System to deliver the TUSC2 tumor-suppressor gene through a lipid-based nanoparticle. The therapy is being evaluated in clinical development programmes for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Genprex reports that the FDA has granted Fast Track Designation to both lung cancer programmes and Orphan Drug Designation to its small cell lung cancer programme. The company is also advancing an earlier-stage gene therapy programme for diabetes, designed to restore insulin-producing capability through the expression of key pancreatic transcription factors. While the new research explores potential connections between TUSC2, mitochondrial function, and aging-related processes, further investigation will be necessary to establish whether these findings could support future therapeutic development. The research should therefore be viewed as an area of scientific exploration rather than evidence of an established treatment for aging-related conditions.

The planned GSA presentation represents another step in Genprex’s research collaboration with Meharry Medical College and its broader investigation of TUSC2 biology. By examining cellular resilience and molecular aging alongside cancer-related mechanisms, the research may contribute to a wider understanding of the gene’s biological functions and inform future research directions.

Source: Genprex press release